TrimethylamineN-Oxide, the Microbiome, and Heart and Kidney Disease
Another update recommends considering glucagonlike peptide1 [GLP1] receptor agonists for highrisk patients with CVD who have type 2 diabetes, which is in line with the findings of recently published clinical trials, including the LEADER (ClinicalTrials.gov identifier: NCT01179048) trials 2
Patients with genetic markers associated with higher telogen effluvium risk benefit from slower dose escalation, closer nutritional monitoring, and sometimes dual-compound protocols (like GLP-Squared Injection) that distribute metabolic stress more evenly across peptide pathways
We administer glutathione through an IV push
DPP-4 Inhibitors DPP-4 inhibitors did not show cardiovascular benefits in meta-analyses by other researchers and ourselves.16,17,55 A previous meta-analysis concluded significant reductions in MACE, but the inclusion of trials with shorter follow-up periods may limit the robustness of the conclusions
(2020) reveals that the fluorescent signal inside the ventricles of a cleared mouse brain after i.p
